Limits...
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB - Oncotarget (2015)

Bottom Line: Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively.Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH.No obvious side effects of Rapatar were detected.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.

ABSTRACT
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

No MeSH data available.


Related in: MedlinePlus

Relative weight of the ventral lobe and or lateral+dorsal lobes of the prostateLobes weight (mg) divided by total body weight (g). Values are means ± SE; Control +T and TBPH groups n = 9, other groups n = 10. Animals were treated as described in Table 1. Superscript signs show significant difference: * – from Control-T or Control-S, ** - p < 0.01, *p < 0.05, # – from TBPH or SBPH, ## - p < 0.01, # - p < 0.05. R – Rapatar; F- Finasteride.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496392&req=5

Figure 1: Relative weight of the ventral lobe and or lateral+dorsal lobes of the prostateLobes weight (mg) divided by total body weight (g). Values are means ± SE; Control +T and TBPH groups n = 9, other groups n = 10. Animals were treated as described in Table 1. Superscript signs show significant difference: * – from Control-T or Control-S, ** - p < 0.01, *p < 0.05, # – from TBPH or SBPH, ## - p < 0.01, # - p < 0.05. R – Rapatar; F- Finasteride.

Mentions: Testosterone induced a 1.6-fold increase in the ventral lobe weight (Figure 1A). Finasteride but not Rapatar prevented weight gain of prostate lobes. Yet, as shown in our study (below), Rapatar prevented hyperplastic and degenerative histological abnormalities and inflammation caused by testosterone.


Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB - Oncotarget (2015)

Relative weight of the ventral lobe and or lateral+dorsal lobes of the prostateLobes weight (mg) divided by total body weight (g). Values are means ± SE; Control +T and TBPH groups n = 9, other groups n = 10. Animals were treated as described in Table 1. Superscript signs show significant difference: * – from Control-T or Control-S, ** - p < 0.01, *p < 0.05, # – from TBPH or SBPH, ## - p < 0.01, # - p < 0.05. R – Rapatar; F- Finasteride.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496392&req=5

Figure 1: Relative weight of the ventral lobe and or lateral+dorsal lobes of the prostateLobes weight (mg) divided by total body weight (g). Values are means ± SE; Control +T and TBPH groups n = 9, other groups n = 10. Animals were treated as described in Table 1. Superscript signs show significant difference: * – from Control-T or Control-S, ** - p < 0.01, *p < 0.05, # – from TBPH or SBPH, ## - p < 0.01, # - p < 0.05. R – Rapatar; F- Finasteride.
Mentions: Testosterone induced a 1.6-fold increase in the ventral lobe weight (Figure 1A). Finasteride but not Rapatar prevented weight gain of prostate lobes. Yet, as shown in our study (below), Rapatar prevented hyperplastic and degenerative histological abnormalities and inflammation caused by testosterone.

Bottom Line: Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively.Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH.No obvious side effects of Rapatar were detected.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemical Carcinogenesis, Blokhin Cancer Research Center, Moscow, Russia.

ABSTRACT
Benign prostatic hyperplasia (BPH) is the most common age-related disease in men. Here we tested the efficacy of Rapatar, a micellar nanoformulation of rapamycin, in two rat models of BPH: testosterone-induced and sulpiride-induced hyperplasia in ventral lobes and lateral/dorsal lobes, respectively. We found that Rapatar prevented hypertrophic and hyperplastic abnormalities and degenerative alterations in both BPH models. Rapatar normalized weight of the lateral lobes in sulpiride-induced BPH, the most relevant animal model of human BPH. Unlike Finasteride, a standard therapy of BPH, Rapatar reduced inflammation caused by sulpiride. No obvious side effects of Rapatar were detected. Our data provide a rationale for clinical trials of Rapatar in patients suffering from BPH.

No MeSH data available.


Related in: MedlinePlus